Synthetic progestogens and pharmaceutical compositions comprising the same
Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
1. A pharmaceutical composition comprising:
6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone in the form of particles that have a surface area ranging from about 2000 cm 2 /g to about 8500 cm 2 /g, wherein the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone is present in an amount ranging from 2 milligrams (mg) to 6 mg; and
one or more pharmaceutically acceptable excipients,
wherein the pharmaceutical composition does not comprise estrogen; and
wherein the pharmaceutical composition is formulated such that,
(1) when orally administered to a patient under fasting conditions, the pharmaceutical composition provides a pharmacokinetic profile for the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone comprising:
(i) a mean T max ranging from 2.2 hours to 6 hours; and
(ii) a mean C max of less than 30 ng/ml; and (no more than 50% of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 30 minutes if subjected to an in vitro dissolution test according to the USP XXIII Paddle Method.
2. The pharmaceutical composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises a filler.
3. The pharmaceutical composition of claim 2 , wherein the filler comprises lactose anhydrous, microcrystalline cellulose, starch, pregelatinized starch, modified starch, dibasic calcium phosphate dihydrate, calcium sulfate trihydrate, calcium sulfate dihydrate, calcium carbonate, lactose, dextrose, sucrose, mannitol, sorbitol, or a combination thereof.
4. The pharmaceutical composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises a lubricant.
5. The pharmaceutical composition of claim 4 , wherein the lubricant comprises magnesium stearate, calcium stearate, zinc stearate, talc, propylene glycol, PEG, stearic acid, vegetable oil, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, mineral oil polyoxyethylene monostearate, or a combination thereof.
6. The pharmaceutical composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises a binder.
7. The pharmaceutical composition of claim 6 , wherein the binder comprises a starch, a gum, microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, or a combination thereof.
8. The pharmaceutical composition of claim 7 , wherein the starch comprises potato starch, wheat starch, corn starch, or a combination thereof.
9. The pharmaceutical composition of claim 7 , wherein the gum comprises gum tragacanth, acacia gum, gelatin, or a combination thereof.
10. The pharmaceutical composition of claim 1 , wherein the one or more pharmaceutically acceptable excipients comprises a glidant.
11. The pharmaceutical composition of claim 10 , wherein the glidant comprises silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc, tribasic calcium phosphate, or a combination thereof.
12. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated as a tablet or a capsule.
13. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition further comprises a coating.
14. The pharmaceutical composition of claim 13 , wherein the coating comprises hydroxypropylmethyl cellulose, hydroxypropyl cellulose, ethyl cellulose, or a combination thereof.
15. The pharmaceutical composition of claim 1 ,
wherein the pharmaceutical composition is formulated such that at least 55% of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone initially present in the pharmaceutical composition is dissolved within 4 hours if subjected to the in vitro dissolution test according to the USP XXIII Paddle Method.
16. The pharmaceutical composition of claim 1 , wherein
the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present ranges from 3.0 mg to 3.5 mg.
17. The pharmaceutical composition of claim 1 , wherein the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present is about 3.5 mg.
18. The pharmaceutical composition of claim 1 , wherein the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present is about 4.0 mg.
19. The pharmaceutical composition of claim 1 , wherein the pharmacokinetic profile for the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone further comprises an AUC 0 h −t last of at least 350 ng*h/ml.
20. The pharmaceutical composition of claim 1 , wherein the pharmacokinetic profile for the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone further comprises an AUC 0 h −t last of at least 300 ng*h/ml.
21. The pharmaceutical composition of claim 1 , wherein the surface area ranges from 2000 cm 2 /g to 8500 cm 2 /g.
22. The pharmaceutical composition of claim 15 , wherein the surface area ranges from 2000 cm 2 /g to 8500 cm 2 /g.
23. The pharmaceutical composition of claim 19 , wherein the surface area ranges from 2000 cm 2 /g to 8500 cm 2 /g.
24. The pharmaceutical composition of claim 20 , wherein the surface area ranges from 2000 cm 2 /g to 8500 cm 2 /g.
25. The pharmaceutical composition of claim 21 , wherein the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present ranges from 3.0 mg to 4.5 mg.
26. The pharmaceutical composition of claim 22 , wherein the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present ranges from 3.0 mg to 4.5 mg.
27. The pharmaceutical composition of claim 23 , wherein the amount of the 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone present ranges from 3.0 mg to 4.5 mg.